v3.24.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Stock-based compensation expense is included on the Condensed Consolidated Statements of Income and Comprehensive Income based upon the job function of the employees receiving the grants as follows (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Lease and Well$22 $16 $50 $39 
Gathering, Processing and Transportation Costs2 1 5 3 
Exploration Costs8 8 20 18 
General and Administrative26 32 73 66 
Total$58 $57 $148 $126 
Schedule of Weighted Average Fair Values and Valuation Assumptions Weighted average fair values and valuation assumptions used to value ESPP grants during the nine-month periods ended September 30, 2024 and 2023 are as follows:
ESPP
Nine Months Ended
September 30,
 20242023
Weighted Average Fair Value of Grants$26.03 $29.39 
Expected Volatility25.78 %38.07 %
Risk-Free Interest Rate5.17 %5.02 %
Dividend Yield2.87 %2.67 %
Expected Life0.5 years0.5 years
Schedule of Stock Options and SARs Transactions
The following table sets forth stock option and SAR transactions for the nine-month periods ended September 30, 2024 and 2023 (stock options and SARs in thousands):
Nine Months Ended
September 30, 2024		Nine Months Ended
September 30, 2023
Number of
Stock
Options/SARs		Weighted
Average
Exercise
Price		Number of
Stock
Options/SARs		Weighted
Average
Exercise
Price
Outstanding at January 12,843 $79.22 4,225 $77.49 
Exercised (1)
(882)75.46 (924)76.88 
Forfeited(33)86.69 (78)86.69 
Outstanding at September 30 (2)
1,928 $80.81 3,223 $77.45 
Vested or Expected to Vest (3)
1,928 $80.81 3,175 $77.38 
Exercisable at September 30 (4)
1,926 $80.80 2,646 $76.53 
(1)The total intrinsic value of stock options/SARs exercised during the nine months ended September 30, 2024 and 2023 was $46 million in both periods. The intrinsic value is based upon the difference between the market price of EOG's common stock on the date of exercise and the exercise price of the stock options/SARs.
(2)The total intrinsic value of stock options/SARs outstanding at September 30, 2024 and 2023 was $83 million and $159 million, respectively. At September 30, 2024 and 2023, the weighted average remaining contractual life was 2.7 years and 3.6 years, respectively.
(3)The total intrinsic value of stock options/SARs vested or expected to vest at September 30, 2024 and 2023 was $83 million and $157 million, respectively. At September 30, 2024 and 2023, the weighted average remaining contractual life was 2.7 years and 3.6 years, respectively.
(4)The total intrinsic value of stock options/SARs exercisable at September 30, 2024 and 2023 was $83 million and $133 million, respectively. At September 30, 2024 and 2023, the weighted average remaining contractual life was 2.7 years and 3.3 years, respectively.
Schedule of Restricted Stock and Restricted Stock Unit Transactions
The following table sets forth restricted stock and restricted stock unit transactions for the nine-month periods ended September 30, 2024 and 2023 (shares and units in thousands):
Nine Months Ended
September 30, 2024		Nine Months Ended
September 30, 2023
Number of
Shares and
Units		Weighted
Average
Grant Date
Fair Value		Number of
Shares and
Units		Weighted
Average
Grant Date
Fair Value
Outstanding at January 14,364 $111.24 4,113 $80.77 
Granted1,822 122.35 1,629 131.33 
Released (1)
(1,264)85.21 (1,208)40.27 
Forfeited(143)113.78 (85)84.25 
Outstanding at September 30 (2)
4,779 $122.28 4,449 $110.21 
(1)The total intrinsic value of restricted stock and restricted stock units released during the nine months ended September 30, 2024 and 2023, was $155 million and $156 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the restricted stock and restricted stock units are released.
(2)The total intrinsic value of restricted stock and restricted stock units outstanding at September 30, 2024 and 2023, was $588 million and $564 million, respectively.
Schedule of Performance Award Transactions
The following table sets forth the Performance Unit transactions for the nine-month periods ended September 30, 2024 and 2023 (units in thousands):
Nine Months Ended
September 30, 2024		Nine Months Ended
September 30, 2023
Number of
Units		Weighted
Average
Grant Date Fair Value		Number of
Units		Weighted
Average
Grant Date Fair Value
Outstanding at January 1630 $95.49 688 $83.82 
Granted109 130.31 109 141.59 
Released (1)
(45)43.33 (86)79.98 
Forfeited for Performance Multiple (2)
(135)43.33 (86)79.98 
Outstanding at September 30 (3)
559 (4)$119.05 625 $94.94 
(1)The total intrinsic value of Performance Units released was $5 million and $10 million for the nine months ended September 30, 2024 and 2023, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the Performance Units are released.
(2)Upon completion of the Performance Period for the Performance Units granted in 2020 and 2019, a performance multiple of 25% and 50%, respectively, was applied to each of the grants resulting in a forfeiture of Performance Units in February 2024 and February 2023.
(3)The total intrinsic value of Performance Units outstanding at September 30, 2024 and 2023, was $69 million and $79 million, respectively.
(4)Upon the application of the relevant performance multiple at the completion of each of the remaining Performance Periods, a minimum of zero and a maximum of 1,118 Performance Units could be outstanding.